CD79B and diffuse large B-cell lymphoma: Near complete reduction of pAKT-308 and pAKT-473 levels was noted with 200 nM CAL-101 in three ABC DLBCL lines (TMD8, HBL1, Ly10) with concurrent BCR (CD79A or CD79B) and MYD88 (L265P) mutations, whereas CAL-101 at high concentrations (1600 nM) had little or no effect on PI3K activity in other ABC DLBCL lines (Figure 1C).